Pioneering solutions for obesity and type 2 diabetes

As the quest for the ultimate solution to type 2 diabetes heats up, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) agonists have emerged as game-changing treatments, revolutionising the management of type 2 diabetes and obesity. Brands such as Ozempic®, Mounjaro®, and Wegovy® are generating significant buzz, offering patients renewed hope for better glycaemic control and weight loss.

Pharmaceutical giants Eli Lilly and Novo Nordisk are at the forefront of these innovative therapies. According to JP Morgan’s research, by 2030, 9% of the US population could be using a GLP-1 agonist, potentially driving the market to over $100 billion. The increasing prevalence of these diseases, combined with the introduction of new treatments, has spurred rapid growth in the GLP-1 market, capturing the interest of many stakeholders.

The development of GIP and GLP-1 agonists for type 2 diabetes and obesity has garnered significant attention within the pharmaceutical industry. Eli Lilly and Novo Nordisk have carved out distinctive brands to address these health issues, with type 2 diabetes currently commanding a larger market share.

Novo Nordisk has developed several GLP-1 agonists using semaglutide as the active ingredient. After the FDA approved Ozempic® for type 2 diabetes treatment in 2017, it swiftly became a market leader, generating over $14 billion in sales by 2023. This medication was also repackaged and marketed as Wegovy® for obesity management. Novo Nordisk expanded its offerings further by introducing Rybelsus® in 2019, the first approved oral GLP-1 agonist for type 2 diabetes.

Eli Lilly has created a series of GLP-1 agonists with tirzepatide as the active ingredient. Unlike semaglutide, tirzepatide offers a dual-action approach, acting as both a GIP and GLP-1 agonist. Building on the success of Trulicity® (dulaglutide), Eli Lilly launched Mounjaro® in 2022 for type 2 diabetes management. Research indicates that tirzepatide’s dual-action response may provide superior glycaemic control and more significant weight loss. Eli Lilly continued its innovation with the approval of Zepbound® in late 2023 for obesity management.

The future of GLP-1 agonists is promising, with Pfizer in the late stages of developing an oral GLP-1 agonist. Concurrently, Amgen is exploring a novel approach with a GLP-1 agonist that specifically inhibits GIP receptors.

With the rising prevalence of obesity, the GLP-1 market holds substantial potential. The World Obesity Federation estimates that by 2035, one in four individuals will be obese, and another one in four will be overweight. This surge will significantly impact healthcare costs, with the global economic burden projected to exceed $4 trillion annually. This expenditure is comparable to the financial impact of the Covid-19 pandemic in 2020, underscoring the vast market opportunity for pharmaceutical companies.

JP Morgan’s study predicts that by 2030, 9% of the US population will use GLP-1 agonists, driving the market to surpass $100 billion.

The effectiveness of GLP-1 agonists in addressing obesity has brought this issue into the spotlight. High-profile endorsements from figures like Elon Musk and Oprah Winfrey have increased the popularity of these weight-loss medications in the United States. However, the limited availability of Wegovy® has led doctors to prescribe Ozempic® off-label for weight loss, creating challenges for type 2 diabetes patients worldwide.

In response to the growing demand, Novo Nordisk announced an 80% increase in their investment in Wegovy® production for 2024, amounting to $6.5 billion. As stakeholders aim to tap into the potential $100 billion market, this investment highlights the impact of GLP-1 agonists on the weight management industry and the importance of ensuring their accessibility.

The rise of obesity and its link to type 2 diabetes has driven a significant shift in the pharmaceutical landscape, with GIP and GLP-1 agonists offering a promising solution. However, the growing demand for these medications, especially for weight management, has led to supply and accessibility challenges, as seen with the Wegovy® shortage. As the industry strives to meet the needs of a burgeoning population affected by obesity and type 2 diabetes, continued investment and innovation will be vital to ensuring the availability and affordability of these life-changing therapies for all who need them.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams. The Talking Medicines mission is to be the World’s Gold Standard for Patient Intelligence by Medicine.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Tern plc

More articles like this

Tern plc

Cybersecurity complexities in the medical device industry

Paul Lockley – VP Sales, EMEA: Recently, I had the pleasure of speaking at the 6th Annual European Medical Device and Diagnostic Cybersecurity Conference. The event covered a wide range of cyber-related issues, including SBOM complexities, the

Tern plc

The opportunities of AI in healthcare

Talking Medicines co-founder Scott Crae was invited by the Ethical Medicines Industry Group (EMIG) to present on the opportunities for AI tools in a data-driven healthcare environment. EMIG is a multi-stakeholder network and trade association representing

Tern plc

Why Privileged Access Management is essential for cybersecurity

Privileged Access Management (PAM) is fundamental to cybersecurity strategies, monitoring and protecting privileged accounts that have the authority to make significant changes within IT environments. It plays a crucial role in safeguarding against internal and external

Tern plc

Unlocking the potential of IoT through satellite connectivity

The Internet of Things (IoT) excites many due to its potential to surface critical information swiftly, bypassing the delays of human intervention. By leveraging real-time data, businesses can achieve efficiencies, support innovative business models, and derive

Tern plc

Medical training with AI and VR

The convergence of Immersive Virtual Reality (VR) and Artificial Intelligence (AI) is transforming medical training, offering personalised learning experiences, enhancing engagement, and empowering educators with real-time insights. Despite the challenges and considerations, the benefits of AI

Tern plc

Securing networks with IAM Zero Trust

In today’s security landscape, the assumption of trust is no longer viable, necessitating a stringent approach to network protection. IAM Zero Trust embodies this by enforcing the principle of ‘never trust, always verify.’ This model requires

Tern plc

Growing the Internet of Things to ensure success

The Internet of Things (IoT) is expanding rapidly, with an ever-increasing number of devices and use cases marking the advent of a new era in connectivity. Advances in artificial intelligence are significantly contributing to this growth.

FundamentalVR announces groundbreaking AI integration in surgical training

FundamentalVR, a global leader in immersive surgical training, has made significant advancements in its Fundamental Surgery platform by integrating cutting-edge artificial intelligence (AI) capabilities. These enhancements aim to drive predictive insights, improve surgical proficiency, and accelerate

Tern plc

Developing and maintaining Identity and Access Management policies

Safeguarding your business’s digital assets while providing appropriate access levels is crucial. Identity and Access Management (IAM) policies play a vital role in organisational security, ensuring that only authorised individuals have access to critical systems and

Tern plc

AI is revolutionising healthcare strategies

In the dynamic landscape of healthcare, the continuous evolution of drug development and patient engagement necessitates ongoing innovation. Recently, GLP-1 drugs have garnered considerable attention for their revolutionary impact on treating various medical conditions, including weight

Tern plc

Understanding Identity Access Management solutions

Identity Access Management (IAM) solutions play a critical role in minimising cyber and data governance risks by tracking and restricting access to digital systems. Fundamentally, IAM solutions capture and log user login information, manage the database

Tern plc

Device Authority welcomes new VP of Customer Success

Device Authority, a recognised global leader in Identity and Access Management (IAM) for Enterprise IoT ecosystems, has announced the addition of Steve Huehmer, an experienced Customer Success expert, to their team. Steve Huehmer, based in Boston,

Revolutionising global IoT connectivity

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams. Wyld Networks is uniquely placed to deliver fixed and mobile mesh technology

Tern plc

Tern’s FY23 results show promising metrics and strategic growth

Tern’s FY23 results showcase improving metrics that are likely to attract additional strategic interest across its portfolio. All companies within Tern’s portfolio are experiencing significant commercial traction. Configuration work is transitioning to repeat licencing through SaaS